SE9702799D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9702799D0
SE9702799D0 SE9702799A SE9702799A SE9702799D0 SE 9702799 D0 SE9702799 D0 SE 9702799D0 SE 9702799 A SE9702799 A SE 9702799A SE 9702799 A SE9702799 A SE 9702799A SE 9702799 D0 SE9702799 D0 SE 9702799D0
Authority
SE
Sweden
Prior art keywords
alkyl
cycloalkyl
enantiomers
alkoxy
aryl
Prior art date
Application number
SE9702799A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Berg
Mats Linderberg
Svante Ross
Seth-Olov Thorberg
Bengt Ulff
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9702799A priority Critical patent/SE9702799D0/xx
Publication of SE9702799D0 publication Critical patent/SE9702799D0/xx
Priority to TW087111330A priority patent/TW438781B/zh
Priority to KR1020007000743A priority patent/KR20010022171A/ko
Priority to JP2000504131A priority patent/JP3895923B2/ja
Priority to ES98934104T priority patent/ES2187983T3/es
Priority to US09/171,577 priority patent/US6313118B1/en
Priority to DE69809755T priority patent/DE69809755T2/de
Priority to PT98934104T priority patent/PT1000048E/pt
Priority to EEP200000041A priority patent/EE04238B1/xx
Priority to EP98934104A priority patent/EP1000048B1/de
Priority to PCT/SE1998/001390 priority patent/WO1999005134A1/en
Priority to SI9830343T priority patent/SI1000048T1/xx
Priority to AU83703/98A priority patent/AU739569B2/en
Priority to PL98338563A priority patent/PL338563A1/xx
Priority to YU2300A priority patent/YU2300A/sh
Priority to CA002296518A priority patent/CA2296518A1/en
Priority to MA25169A priority patent/MA26521A1/fr
Priority to SK1883-99A priority patent/SK283918B6/sk
Priority to CN98809246A priority patent/CN1270585A/zh
Priority to IL13410898A priority patent/IL134108A0/xx
Priority to UA2000021064A priority patent/UA69389C2/uk
Priority to AT98934104T priority patent/ATE228510T1/de
Priority to IDW20000122A priority patent/ID24583A/id
Priority to NZ502384A priority patent/NZ502384A/en
Priority to TR2000/00229T priority patent/TR200000229T2/xx
Priority to BR9811042-0A priority patent/BR9811042A/pt
Priority to HU0004334A priority patent/HUP0004334A3/hu
Priority to DK98934104T priority patent/DK1000048T3/da
Priority to RU2000104802/04A priority patent/RU2194696C2/ru
Priority to DZ980179A priority patent/DZ2569A1/xx
Priority to TNTNSN98141A priority patent/TNSN98141A1/fr
Priority to ZA986588A priority patent/ZA986588B/xx
Priority to HR980404A priority patent/HRP980404B1/xx
Priority to ARP980103667A priority patent/AR013370A1/es
Priority to NO20000356A priority patent/NO315609B1/no
Priority to IS5358A priority patent/IS5358A/is
Priority to HK00105178A priority patent/HK1025963A1/xx
Priority to US09/902,123 priority patent/US6534652B2/en
Priority to US09/902,000 priority patent/US6410532B2/en
Priority to ARP040103875A priority patent/AR046193A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9702799A 1997-07-25 1997-07-25 New compounds SE9702799D0 (sv)

Priority Applications (40)

Application Number Priority Date Filing Date Title
SE9702799A SE9702799D0 (sv) 1997-07-25 1997-07-25 New compounds
TW087111330A TW438781B (en) 1997-07-25 1998-07-13 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AT98934104T ATE228510T1 (de) 1997-07-25 1998-07-15 Substituierte 1,2,3,4-tetrahydronaphthalin derivate
CN98809246A CN1270585A (zh) 1997-07-25 1998-07-15 取代的1,2,3,4－四氢化萘衍生物
CA002296518A CA2296518A1 (en) 1997-07-25 1998-07-15 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
ES98934104T ES2187983T3 (es) 1997-07-25 1998-07-15 Derivados 1,2,3,4-tetrahidronaftaleno sustituidos.
US09/171,577 US6313118B1 (en) 1997-07-25 1998-07-15 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
DE69809755T DE69809755T2 (de) 1997-07-25 1998-07-15 Substituierte 1,2,3,4-tetrahydronaphthalin derivate
PT98934104T PT1000048E (pt) 1997-07-25 1998-07-15 Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
EEP200000041A EE04238B1 (et) 1997-07-25 1998-07-15 Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid, meetod selle valmistamiseks, nimetatud terapeutilise toimega aineid sisaldavad ravimkoostised ja nimetatud aktiivsete ühendite kasutamine teraapias
EP98934104A EP1000048B1 (de) 1997-07-25 1998-07-15 Substituierte 1,2,3,4-tetrahydronaphthalin derivate
UA2000021064A UA69389C2 (uk) 1997-07-25 1998-07-15 Заміщені похідні 1,2,3,4-тетрагідронафталіну, спосіб їх одержання, фармацевтична композиція та проміжні продукти для їх одержання
SI9830343T SI1000048T1 (en) 1997-07-25 1998-07-15 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AU83703/98A AU739569B2 (en) 1997-07-25 1998-07-15 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
PL98338563A PL338563A1 (en) 1997-07-25 1998-07-15 Substituted derivatives of 1,2,3,4-tetrahydronaphtalene
YU2300A YU2300A (sh) 1997-07-25 1998-07-15 Derivati supstituisanog 1,2,3,4-tetrahidronaftalina
JP2000504131A JP3895923B2 (ja) 1997-07-25 1998-07-15 置換された１，２，３，４−テトラヒドロナフタレン誘導体
MA25169A MA26521A1 (fr) 1997-07-25 1998-07-15 Derives de 1,2,3,4-tetrahydronaphthalene substitue.
SK1883-99A SK283918B6 (sk) 1997-07-25 1998-07-15 Substituované deriváty 1,2,3,4-tetrahydronaftalénu, spôsob ich prípravy, medziprodukty na ich prípravu, farmaceutické prípravky s ich obsahom a ich použitie
KR1020007000743A KR20010022171A (ko) 1997-07-25 1998-07-15 치환된 1,2,3,4-테트라히드로나프탈렌 유도체
IL13410898A IL134108A0 (en) 1997-07-25 1998-07-15 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
PCT/SE1998/001390 WO1999005134A1 (en) 1997-07-25 1998-07-15 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
RU2000104802/04A RU2194696C2 (ru) 1997-07-25 1998-07-15 Производные 1,2,3,4-тетрагидронафталина, способы их получения, фармацевтическая композиция на их основе и способ лечения
DK98934104T DK1000048T3 (da) 1997-07-25 1998-07-15 Substituerede 1,2,3,4-tetrahydronapthalenderivater
NZ502384A NZ502384A (en) 1997-07-25 1998-07-15 Substituted 1,2,3,4-tetrahydronaphthalene derivatives as serotonin receptor antagonists
TR2000/00229T TR200000229T2 (tr) 1997-07-25 1998-07-15 İkame edilmiş 1,2,3,4-Tetrahidronaftalen türevle i
BR9811042-0A BR9811042A (pt) 1997-07-25 1998-07-15 Composto, formulação farmacêutica, uso de um composto, e, processos para o tratamento de distúrbios no sistema nervoso central e/ou de incontinência urinária, vasoespasmos e controle do crescimento de tumores e para a preparação do composto
HU0004334A HUP0004334A3 (en) 1997-07-25 1998-07-15 Substituted 1,2,3,4-tetrahydronaphthalene derivatives, process for producing them and pharmaceutical compositions containing them
IDW20000122A ID24583A (id) 1997-07-25 1998-07-15 Turunan-turunan 1,2,3,4-tetrahidronaftalena tersubstitusi
DZ980179A DZ2569A1 (fr) 1997-07-25 1998-07-22 Dérivés 1,2,3,4-tétrahydronaphtalène substitués.
HR980404A HRP980404B1 (en) 1997-07-25 1998-07-23 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
TNTNSN98141A TNSN98141A1 (fr) 1997-07-25 1998-07-23 Derives 1,2,3, 4-tetrahydronapthalene substitues
ZA986588A ZA986588B (en) 1997-07-25 1998-07-23 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
ARP980103667A AR013370A1 (es) 1997-07-25 1998-07-24 Derivados de 1,2,3,4-tetrahidronaftaleno sustituidos, formulacion farmaceutica que los comprende, su uso en la manufactura de un medicamento,proceso para su preparacion y compuestos intermediarios
NO20000356A NO315609B1 (no) 1997-07-25 2000-01-24 Substituerte 1,2,3,4-tetrahydronaftalenderivater, farmasöytisk formuleringinneholdende slike, fremgangsmåte for deres fremstilling, oganvendelse derav
IS5358A IS5358A (is) 1997-07-25 2000-01-24 Útskiptar 1,2,3,4-tetrahýdrónaftalen afleiður
HK00105178A HK1025963A1 (en) 1997-07-25 2000-08-17 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
US09/902,123 US6534652B2 (en) 1997-07-25 2001-07-10 Intermediates for the preparation of substituted 1,2,3,4-tetrahydronaphthalene derivatives
US09/902,000 US6410532B2 (en) 1997-07-25 2001-07-10 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
ARP040103875A AR046193A2 (es) 1997-07-25 2004-10-25 Derivados de piperidil o piperazinil 1,2,3,4-tetrahidronaftaleno sustituido, formulacion farmaceutica, usos en la manufactura de medicamentos, y proceso para su preparacion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702799A SE9702799D0 (sv) 1997-07-25 1997-07-25 New compounds

Publications (1)

Publication Number Publication Date
SE9702799D0 true SE9702799D0 (sv) 1997-07-25

Family

ID=20407828

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702799A SE9702799D0 (sv) 1997-07-25 1997-07-25 New compounds

Country Status (37)

Country Link
US (3) US6313118B1 (de)
EP (1) EP1000048B1 (de)
JP (1) JP3895923B2 (de)
KR (1) KR20010022171A (de)
CN (1) CN1270585A (de)
AR (2) AR013370A1 (de)
AT (1) ATE228510T1 (de)
AU (1) AU739569B2 (de)
BR (1) BR9811042A (de)
CA (1) CA2296518A1 (de)
DE (1) DE69809755T2 (de)
DK (1) DK1000048T3 (de)
DZ (1) DZ2569A1 (de)
EE (1) EE04238B1 (de)
ES (1) ES2187983T3 (de)
HK (1) HK1025963A1 (de)
HR (1) HRP980404B1 (de)
HU (1) HUP0004334A3 (de)
ID (1) ID24583A (de)
IL (1) IL134108A0 (de)
IS (1) IS5358A (de)
MA (1) MA26521A1 (de)
NO (1) NO315609B1 (de)
NZ (1) NZ502384A (de)
PL (1) PL338563A1 (de)
PT (1) PT1000048E (de)
RU (1) RU2194696C2 (de)
SE (1) SE9702799D0 (de)
SI (1) SI1000048T1 (de)
SK (1) SK283918B6 (de)
TN (1) TNSN98141A1 (de)
TR (1) TR200000229T2 (de)
TW (1) TW438781B (de)
UA (1) UA69389C2 (de)
WO (1) WO1999005134A1 (de)
YU (1) YU2300A (de)
ZA (1) ZA986588B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9900190D0 (sv) * 1999-01-22 1999-01-22 Astra Ab New compounds
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
AR034206A1 (es) * 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
SE0102856D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab A new method
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
US7101881B2 (en) * 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV
JP2008500383A (ja) * 2004-05-21 2008-01-10 ファイザー・プロダクツ・インク ５−ｈｔ１ｂアンタゴニスト、インバースアゴニストおよび部分アゴニストとしてのテトラヒドロナフチルピペラジン類
US20080033050A1 (en) * 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
WO2008130321A2 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain
WO2008130323A1 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel 8-piperazine-tetrahydronaphtalene derivatives for the treatment of pain
WO2008130322A1 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel 5-heterocyclyl-chromane derivatives for the treatment of pain
WO2008130319A2 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain
EP2098511A1 (de) 2008-03-07 2009-09-09 Solvias AG Verfahren zur Herstellung von Verbindungen mit einer Hydronaphtalinstruktur mit einem asymmetrisch substituierten Benzolring
PE20110029A1 (es) 2008-06-20 2011-02-11 Astrazeneca Ab Derivados de dibenzotiazepina
GB201002563D0 (en) 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
CA2914263C (en) 2013-06-21 2021-05-18 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3919624A1 (de) 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE69232003T2 (de) 1991-09-18 2002-04-25 Glaxo Group Ltd., Greenford Benzanilidderivate als 5-HT1D-Antagonisten
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
AU6391894A (en) * 1993-03-16 1994-10-11 Pfizer Inc. Naphthalene derivatives
JPH09503773A (ja) 1993-10-19 1997-04-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ−１ｄレセプター拮抗剤用のベンズアニリド誘導体
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
AR046193A2 (es) 2005-11-30
EP1000048B1 (de) 2002-11-27
HRP980404B1 (en) 2002-10-31
IL134108A0 (en) 2001-04-30
DE69809755D1 (de) 2003-01-09
SI1000048T1 (en) 2003-04-30
EE04238B1 (et) 2004-02-16
ATE228510T1 (de) 2002-12-15
WO1999005134A1 (en) 1999-02-04
IS5358A (is) 2000-01-24
SK283918B6 (sk) 2004-05-04
HUP0004334A3 (en) 2002-10-28
NZ502384A (en) 2001-05-25
RU2194696C2 (ru) 2002-12-20
HUP0004334A2 (en) 2001-03-28
ZA986588B (en) 1999-01-25
YU2300A (sh) 2002-10-18
AU739569B2 (en) 2001-10-18
TR200000229T2 (tr) 2000-06-21
CN1270585A (zh) 2000-10-18
BR9811042A (pt) 2000-08-15
KR20010022171A (ko) 2001-03-15
AR013370A1 (es) 2000-12-27
PT1000048E (pt) 2003-03-31
PL338563A1 (en) 2000-11-06
EE200000041A (et) 2000-10-16
JP2001510837A (ja) 2001-08-07
ID24583A (id) 2000-07-27
JP3895923B2 (ja) 2007-03-22
MA26521A1 (fr) 2004-12-20
CA2296518A1 (en) 1999-02-04
US20010051626A1 (en) 2001-12-13
DK1000048T3 (da) 2003-03-03
TW438781B (en) 2001-06-07
NO20000356L (no) 2000-03-27
AU8370398A (en) 1999-02-16
US6410532B2 (en) 2002-06-25
HRP980404A2 (en) 1999-04-30
NO20000356D0 (no) 2000-01-24
UA69389C2 (uk) 2004-09-15
TNSN98141A1 (fr) 2005-03-15
US20010051623A1 (en) 2001-12-13
DZ2569A1 (fr) 2003-02-15
EP1000048A1 (de) 2000-05-17
SK188399A3 (en) 2000-07-11
DE69809755T2 (de) 2003-07-17
ES2187983T3 (es) 2003-06-16
US6313118B1 (en) 2001-11-06
HK1025963A1 (en) 2000-12-01
US6534652B2 (en) 2003-03-18
NO315609B1 (no) 2003-09-29

Similar Documents

Publication Publication Date Title
SE9702799D0 (sv) New compounds
SE9703378D0 (sv) New compounds
SE9703377D0 (sv) New compounds
NZ331613A (en) Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives
HUP0203228A2 (hu) Szubsztituált indolszármazékok az NFKB-aktivitás módosítására, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR025975A1 (es) Compuestos quimicos.
HUP0301249A2 (hu) APO B termelődés gátló benzamid-vegyületek ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE69523169D1 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
HUP0302480A2 (hu) Piridinonszármazékok ateroszklerózis kezelésére, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0300565A2 (hu) PDE 5 inhibitor hatású 8-kinolin-xantin- és 8-izo-kinolin-xantin-származékok, alkalmazásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
SE0101579D0 (sv) New compounds
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
HUP0104058A2 (hu) N-diszubsztituált piperazin vagy 1,4 diszubsztituált piperidin heterociklusos származékai és ezeket tartalmazó gyógyászati készítmények
BG94282A (bg) 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они
PT1216245E (pt) Derivados sulfonil-hidrazida farmaceuticamente activos
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
MY140653A (en) Substituted diketopiperazines and their use as oxytocyn antagonists
HUP0203187A2 (hu) Izoxazolszármazékok mint foszfodiészteráz VII inhibitorok és ezeket tartalmazó gyógyszerkészítmények
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
HUP0201863A2 (hu) Új morfolinszármazékok, eljárás előállításukra és azokat tartalmazó gyógyszerkészítmények
DK1161424T3 (da) Hidtil ukendte diazolderivater som serotonerge midler
YU16196A (sh) Upotreba novih benzohinolin-3-ona i njihovih farmaceutski prihvatljivih soli za proizvodnju leka
HUP0204149A2 (hu) Új szulfoniloxazolamin-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására
NO20020475D0 (no) 2-aminotetralinderivater for terapi av glaukom
ES2027492A6 (es) Procedimiento de preparacion de nuevos derivados dihidropirimidotiazinos y de sus sales de adicion acidas farmaceuticamente aceptables.